Sign in

You're signed outSign in or to get full access.

Richard A. Zordani

Director at GALECTIN THERAPEUTICS
Board

About Richard A. Zordani

Independent director since September 2020; age 53. Director of Shareholder Services at Uline, Inc. since 2013; previously Vice President at Diversified Financial Management Corp. (Pritzker family office) and Audit Manager at Altschuler, Melvoin & Glasser LLP (now RSM McGladrey). Registered CPA (Illinois) with a BS from the University of Illinois at Urbana–Champaign. The Board has designated him an audit committee financial expert and independent under NASDAQ rules.

Past Roles

OrganizationRoleTenureCommittees/Impact
Diversified Financial Management Corp. (Pritzker family office)Director & Vice President advising on complex legal/tax structures2003–2013Finance, tax and governance advisory for entities/trusts
Altschuler, Melvoin & Glasser LLP (now RSM McGladrey)Audit Manager1996–2003Public accounting, audit leadership

External Roles

OrganizationRoleTenureNotes
Uline, Inc.Director of Shareholder Services2013–presentUline is led by Richard E. Uihlein (GALT Chairman); functional proximity to major lender/shareholder to GALT (see Related Party Transactions)

Board Governance

  • Committees: Audit (Chair); members: Zordani (Chair), Kary Eldred, Kevin D. Freeman; met 4 times in 2024. Responsibilities include financial reporting oversight, auditor independence, internal controls, and review/approval of related-party transactions. Zordani designated “audit committee financial expert.”
  • Other committees: Nominating & Governance; Compensation (not listed as member).
  • Independence: Board determined Zordani is independent under NASDAQ and SEC Rule 10A-3 for Audit Committee.
  • Attendance: Board met 7 times in 2024; each director attended at least 75% of Board/committee meetings.
  • Years of service: Director since 2020.

Fixed Compensation

Component (FY2024)Amount ($)Detail
Cash fees55,000Annual director cash plus committee/Chair retainers earned in 2024
Equity (Options) – grant-date fair value58,00050,000 options granted Jan 24, 2024; vest in full Dec 31, 2024; Black-Scholes valuation
Restricted Stock/RSUsNone disclosed for Zordani in 2024
Total113,000Sum of cash and option fair value

Director cash retainer structure (program terms):

  • Base annual retainer: $35,000; Audit Committee member: +$7,500; Audit Committee Chair: +$7,500; Compensation Committee member: +$5,000; Nominating & Governance Committee member: +$3,500; Investor Relations/PR Committee member: +$3,500.

Performance Compensation

Equity AwardGrant Date# OptionsExercise PriceVestingFair Value ($)
Non-employee director option grantJan 24, 202450,000$1.72Vests 100% on Dec 31, 202458,000
  • No director performance-conditioned metrics disclosed (e.g., TSR, revenue, EBITDA). Options are time-vested; equity mix aligns director incentives with shareholder value through stock price appreciation.

Other Directorships & Interlocks

Person/EntityConnectionPotential Interlock/Exposure
Richard E. UihleinGALT Chairman; Uline CEO/Chairman; major GALT lender and holderMultiple convertible notes/lines of credit and warrants provided to GALT by Uihlein; Zordani’s Uline role creates proximity to a related party overseen by Audit Committee he chairs

Expertise & Qualifications

  • CPA (Illinois); audit and financial reporting expertise; designated Audit Committee financial expert.
  • Corporate finance/tax structuring for complex entities and trusts (Pritzker family office).
  • Shareholder services and governance practices in a large private enterprise (Uline).

Equity Ownership

Metric (as of Sep 22, 2025)ValueNotes
Total beneficial ownership (Common)284,853 sharesIncludes rights exercisable within 60 days per SEC rules
Ownership % of Common<1%Denoted “*” in proxy
Options exercisable within 60 days240,000Director options exercisable within 60 days of Oct 1, 2025
Director options held (Dec 31, 2024)240,000Total options outstanding at year-end
Pledged sharesNot disclosedNo pledging disclosure specific to Zordani

Governance Assessment

  • Strengths:

    • Audit Committee Chair with CPA credentials; designated financial expert — supports robust oversight of reporting and controls.
    • Confirmed independence under NASDAQ and SEC Rule 10A-3; attended at least 75% of meetings.
    • Director compensation moderate and equity-linked via options; aligns with shareholder outcomes.
  • Risks and potential conflicts:

    • Related-party concentration: GALT’s financing heavily reliant on Chairman Richard E. Uihlein via multiple convertible notes, lines of credit, warrant issuances (2017–2025), and conversions; Audit Committee (chaired by Zordani) is responsible for related-party oversight. Zordani’s concurrent Uline role increases perceived conflict risk in supervising transactions involving Uihlein/Uline sphere.
    • Hedging policy: Company has not adopted an anti-hedging policy; may weaken alignment safeguards for directors/executives though Insider Trading Policy exists.
    • Control/ownership: Uihlein beneficially owns ~46.1%–48.4% equivalent voting power through common, warrants, and convertible notes; outsized influence can limit minority investor voice.
  • Shareholder signals:

    • Say-on-pay approval ~90% (2022), suggesting broad support for compensation practices; Board recommends triennial say-on-pay and is again seeking advisory approval in 2025.

RED FLAGS

  • Chairing Audit Committee while employed at Uline (led by GALT’s principal lender/chairman) in the presence of extensive related-party financing may present perceived independence challenges despite formal independence designation; vigilance on recusals/robust related-party review is warranted.
  • Absence of an anti-hedging policy could permit transactions that weaken alignment.